Literature DB >> 10973842

Pulmonary release and coronary and peripheral consumption of big endothelin and endothelin-1 in severe heart failure: acute effects of vasodilator therapy.

K Stangl1, T Dschietzig, C Richter, M Laule, V Stangl, E Tanis, G Baumann, S B Felix.   

Abstract

BACKGROUND: We investigated plasma endothelin (ET) levels in patients with congestive heart failure (CHF) during treatment for acute decompensation; we also measured imbalances in ET peptides across the pulmonary, coronary, and peripheral circulation. Methods and Results-In patients with severe CHF (n=21; cardiac index [CI], 1.9+/-0.2 L. min(-1). m(-2); pulmonary capillary wedge pressure [PCWP], 31+/-1 mm Hg), vasodilation was achieved with the nitric oxide donor sodium nitroprusside (n=11) or with the alpha(1)-antagonist urapidil (nitric oxide-independent, n=10). ET concentrations were determined from arterial blood and blood from the pulmonary artery, coronary sinus, and antecubital vein. Depending on sites of measurement, baseline big ET and ET-1 levels were, respectively, 12 to 16 times and 5 to 11 times higher than in controls (n=11), and 4 to 6 times and 2 to 3 times higher than in patients with moderate CHF (n=10; CI, 2.7+/-0.3 L. min(-1). m(-2); PCWP, 14+/-2 mm Hg). Patients with severe CHF demonstrated pulmonary net release and coronary and peripheral net consumption of both peptides (ie, arterial levels [big ET, 7.3+/-1.3 pmol/L; ET-1, 1.8+/-0.1 pmol/L] were higher than levels in the pulmonary artery [6.7+/-1.2 pmol/L; 1. 3+/-0.1 pmol/L], coronary sinus [6.4+/-1.0 pmol/L; 1.4+/-0.1 pmol/L], and antecubital vein [6.6+/-1.1 pmol/L; 1.3+/-0.1 pmol/L]). In these patients, sodium nitroprusside (SNP) and urapidil resulted in comparable hemodynamic improvement after 6 hours (CI: SNP, 63+/-2%; urapidil, 72+/-3%; PCWP: SNP, -50+/-2%; urapidil, -47+/-2%) and a maximum decrease in ET peptides by >50%. After 3 hours, pulmonary net release and coronary and peripheral net consumption were no longer detectable.
CONCLUSIONS: In patients with severe CHF, the lungs act as a producer and the heart and the periphery act as consumers of elevated circulating ETs. Short-term vasodilator therapy decreases ETs and restores their pulmonary, coronary, and peripheral balance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10973842     DOI: 10.1161/01.cir.102.10.1132

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

1.  Transcardiac and transpulmonary gradients in the putative new cardiovascular hormone relaxin.

Authors:  C Fisher; S Al-Benna; A Kirk; J J Morton; J J V McMurray
Journal:  Heart       Date:  2003-07       Impact factor: 5.994

Review 2.  The role of endothelin receptor antagonists in the treatment of chronic heart failure.

Authors:  W Kiowski; G Sütsch
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

Review 3.  The actions of relaxin on the human cardiovascular system.

Authors:  Mohsin Sarwar; Xiao-Jun Du; Thomas B Dschietzig; Roger J Summers
Journal:  Br J Pharmacol       Date:  2016-07-11       Impact factor: 8.739

4.  The transpulmonary ratio of endothelin 1 is elevated in patients with preserved left ventricular ejection fraction and combined pre- and post-capillary pulmonary hypertension.

Authors:  David F Meoli; Yan Ru Su; Evan L Brittain; Ivan M Robbins; Anna R Hemnes; Ken Monahan
Journal:  Pulm Circ       Date:  2017-12-18       Impact factor: 3.017

5.  Effects of human relaxin-2 (serelaxin) on hypoxic pulmonary vasoconstriction during acute hypoxia in a sheep model.

Authors:  René Schiffner; Marius Nistor; Sabine Juliane Bischoff; Georg Matziolis; Martin Schmidt; Thomas Lehmann
Journal:  Hypoxia (Auckl)       Date:  2018-05-22

6.  Effects of Physical Prehabilitation on the Dynamics of the Markers of Endothelial Function in Patients Undergoing Elective Coronary Bypass Surgery.

Authors:  Yulia Argunova; Ekaterina Belik; Olga Gruzdeva; Sergey Ivanov; Svetlana Pomeshkina; Olga Barbarash
Journal:  J Pers Med       Date:  2022-03-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.